LU-CIX increases service reliability and efficiency with ADVA fiber monitoring solution
ADVA (FSE: ADV) today announced that the Luxembourg Commercial Internet Exchange (LU-CIX) is increasing the security and availability of its services with the ADVA ALM fiber monitoring solution. The technology provides real-time network visibility, enabling LU-CIX to quickly locate and resolve all fiber issues. Deployed in the internet exchange company’s backbone infrastructure, the ADVA ALM delivers comprehensive in-service assurance. It’s now empowering LU-CIX to accurately pinpoint areas of degradation, instantly initiate countermeasures and redirect traffic away from degraded optical paths. The compact and low-power solution helps avoid outages and enables LU-CIX to track its SLAs. ADVA’s partner Telindus, a brand of Proximus Luxembourg, also played a key role in the deployment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005221/en/
The ADVA ALM helps LU-CIX to rapidly pinpoint and resolve network issues (Photo: Business Wire)
“We needed a solution that delivers precise, automated, up-to-the-minute root-cause analysis combined with permanent measurement. That’s why we chose the ADVA ALM. It enables our team to tackle issues more quickly and efficiently, while also addressing an area of security exposure,” said Michel Lanners, CIO, LU-CIX. “One of the key advantages of the ADVA ALM is that it offers significant improvement without a major addition to our existing network. It delivers total insight and full control without significant investment. What’s more, the technology enables us to improve the integrity of our network and detect eavesdropping attacks. With the ADVA ALM, we can remotely measure attenuation and stay one step ahead of attacks using a splitter or bending coupler.”
The ADVA ALM is now delivering precise, real-time insight into the integrity and performance of LU-CIX’s optical transport infrastructure. With its ease of use and intuitive GUI, the in-service monitoring equipment provides complete network assurance, enabling the root cause of link outages to be immediately pinpointed. Issues can now be identified in seconds and the right measures engaged, saving the company both time and money. The ADVA ALM also makes it straightforward to separate faults with active devices from problems in the fiber plant. Another key advantage is its transparent, service-agnostic monitoring, which is completely independent of transported data. That means the ADVA ALM delivers complete assurance with no application interference.
“Our ALM now ensures that LU-CIX has an intricate understanding of its fiber network. For maintenance teams, that means no more false alarms, no unnecessary site visits and no wasted hours finding faults. Now problems can be diagnosed and dealt with long before they affect services. Not only will this help to reduce operational expenses and maximize resource efficiency, but it’s also a key tool for maintaining valuable SLAs,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “LU-CIX is crucial to Luxembourg’s internet sector and one of Europe’s key internet hubs. By harnessing our unique plug-and-play device to further enhance the stability and efficiency of its infrastructure, it can continue to provide a secure and trusted environment in the heart of Europe.”
“This deployment is already bringing major benefits to LU-CIX and its customers. It’s enabling the internet exchange to avoid performance issues by rapidly responding to defects and degradation in its fiber network. Now LU-CIX can proactively reroute traffic and operating teams can take targeted action to fix faults,” said William Malingrey, pre-sales consultant, network solutions, Telindus. “We’re committed to providing the most innovative technologies available to support our customers’ business strategies and digital transformation. The ADVA ALM is a uniquely affordable and space-efficient solution that makes a real difference. It’s now giving LU-CIX total visibility and control of its fiber assets and supporting simpler, more cost-efficient and more sustainable practices.”
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
LU-CIX, the LUxembourg Commercial Internet eXchange was founded in 2009 based on a not-for-profit membership association with an open and neutral philosophy. Its aim is to develop the Internet and support the data center community in Luxembourg. As well as providing the technical infrastructure LU-CIX also makes a major contribution to the Luxembourg Internet community through its leading industry event, Luxembourg Internet Days, which takes place in November every year and attracts over a thousand industry experts and decision makers from around the globe. LU-CIX also runs the datacenters-in-europe.com website, which provides a shared communication platform for all the players in the Luxembourg data center and Internet arena and promotes Luxembourg as the best place for your European data center and ICT business in the heart of Europe. More information at www.lu-cix.lu.
ADVA Optical Networking SE, Munich, Germany
t +44 1904 699 358
t +49 89 890 665 854
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
A Continuous Journey of Digital Transformation, Alibaba Cloud and Its Global Customers at Apsara 202018.9.2020 06:00:00 EEST | Press release
As the digital technology and intelligence backbone of Alibaba Group, Alibaba Cloud is experiencing continuous growth alongside its customers across different parts of the world. Over the years, it has made relentless efforts to serve clients from every industry, helping them accelerate their business development and navigate the challenges of these volatile times. Cloud computing and AI technology have been shown to be the cornerstone for businesses seeking to be fully equipped in the digital era, especially following the global outbreak of COVID-19. At the 12th Apsara Conference: Leap into the Future of Digital Intelligence, customers from various sectors, including aviation, leisure and hospitality, education, and e-commerce and retail, share their growth and success stories achieved together with Alibaba Cloud. “It is our utmost pleasure to see our customers experience a seamless transition into more digitalised operations,” said Selina Yuan, President for International Business, A
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer18.9.2020 01:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the first reported data from RATIONALE 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), and the first reported data from the pivotal Phase 2 trial of its investigational PARP inhibitor pamiparib in advanced ovarian cancer (OC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which takes place on September 19-21. “We are pleased to share the promising RATIONALE 304 results, which were used to support our recently accepted supplemental new drug application in first-line non-squamous NSCLC in China,” commented Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene. “BeiGene is evaluating tislelizuma
Sensorion Launches a Capital Increase by Means of an Accelerated Bookbuild Offering17.9.2020 20:33:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, intends to issue new ordinary shares of a nominal value of €0.10 (the “New Shares”) for a total capital increase of approximately €30 million (US$35 million), by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The New Shares will be issued through a share capital increase without shareholders’ preferential subscription rights pursuant to the 12th resolution of the extraordinary general meeting of shareholders of the Company held on May 20, 2020 and in accordance with Article
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom